Form 4: Artiva Biotherapeutics CEO Fred Aslan Reports Stock and Option Awards

CEO Fred Aslan reports the acquisition of restricted stock units and stock options in Artiva Biotherapeutics.

Summary

• On July 22, 2024, Fred Aslan, the President and CEO of Artiva Biotherapeutics, reported the acquisition of 228,905 shares of common stock through a restricted stock unit award.
• The award was granted under the Issuer's 2024 Equity Incentive Plan.
• Aslan also acquired 343,811 employee stock options (Right to Buy) at an exercise price of $12 on July 18, 2024.
• 25% of the shares will vest on July 19, 2025, and the remaining shares vest in 36 equal monthly installments thereafter.
• Following these transactions, Aslan directly owns 228,905 shares of common stock and 343,811 derivative securities.

Sentiment

Score: 7

Explanation: The document reflects standard executive compensation practices, which is generally viewed positively as it aligns management with shareholder interests. The vesting schedule promotes long-term commitment.

Positives

• The grant of restricted stock units and stock options to the CEO aligns his interests with those of the shareholders.
• The vesting schedule of the stock options encourages long-term commitment from the CEO.

Industry Context

Stock and option awards are a common practice in the biotechnology industry to incentivize and retain key executives. These awards align management's interests with those of shareholders by tying a portion of their compensation to the company's stock performance.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotech industry.
• Companies like Amgen, Gilead, and Biogen also use stock options and restricted stock units to incentivize their executives.
• The vesting schedule of the options is typical, with a portion vesting after one year and the remainder vesting over the following years.

Stakeholder Impact

• The stock and option awards could potentially dilute existing shareholders if the options are exercised.
• The awards incentivize the CEO to increase shareholder value.

Key Dates